Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UK55

UPID:
ZPI_HUMAN

ALTERNATIVE NAMES:
Serpin A10

ALTERNATIVE UPACC:
Q9UK55; A5Z2A5; Q6UWX9; Q86U20

BACKGROUND:
The Protein Z-dependent protease inhibitor, known alternatively as Serpin A10, is integral to the coagulation cascade. It uniquely inhibits factor Xa and XIa, crucial enzymes in blood clot formation, under specific conditions involving PROZ, calcium, and phospholipids. This inhibition is essential for controlling blood clotting and ensuring proper blood flow.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Protein Z-dependent protease inhibitor offers a promising avenue for drug discovery. Given its central role in regulating blood clotting, interventions targeting this protein could provide breakthrough therapies for managing thrombotic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.